pre-IPO PHARMA

COMPANY OVERVIEW

Microbiotica was launched in December 2016 with the aim of creating a global leader to exploit the leading microbiome science built at the Wellcome Trust Sanger Institute.


LOCATION

  • Cambridge, , UK

  • THERAPEUTIC AREAS

  • Gastrointestinal Disease
  • Infectious Disease
  • Inflammatory Disease
  • Oncology

  • WEBSITE

    https://microbiotica.com


    CAREER WEBSITE

    https://www.microbiotica.com/careers


    SOCIAL MEDIA


    INVESTORS

    cambridge-innovation-capital ip-group seventure-partners


    PRESS RELEASES


    Apr 12, 2023

    Microbiotica Announces Clinical Trial Collaboration with MSD to Evaluate MB097 in Combination with KEYTRUDA (pembrolizumab) in a Phase 1b Clinical Trial in Melanoma


    Nov 29, 2022

    Microbiotica Announces Transition of Leadership


    Mar 7, 2022

    Microbiotica Raises £50m ($67m) to Advance Pipeline of Microbiome-based Therapeutics


    Jun 23, 2021

    Microbiotica’s Live Bacterial Therapeutic, MB097, in development to begin clinical trials in 2022 in immuno-oncology


    Jun 8, 2020

    Microbiotica, Cancer Research UK and Cambridge University Hospitals Collaborate in Landmark Cancer Microbiome Study


    For More Press Releases


    Google Analytics Alternative